Hungarian drugmakers ask court to strike down new subsidy law
Hungary's biggest pharmaceutical industry group is asking the country's Constitutional Court to strike down the new drug-financing law, saying it places an unfair financial burden on the industry.
The so-called „drug thrift” law violates Hungary's constitution because it forces drugmakers to pay for overspending by the state-monopoly health insurer, the group, Magyosz, said in a statement released yesterday. The law also forces pharmaceutical companies to pay the insurer a 12% rebate on state subsides. Hungary's government passed the law to rein in spending on medicines, which ballooned to Ft 348.9 billion (€1.3 billion) last year, more than double the amount in 2000.
Gedeon Richter Nyrt, Hungary's biggest drugmaker, estimated the law, along with other new taxes and subsidy cuts, may lower 2007 profit by at least Ft 7 billion. „The system doesn't make any sense,” said Robert Wessman, CEO of Icelandic drugmaker Actavis Group hf, whose Hungarian unit, Keri Pharma Kft, is a member of Magyosz. „I'm not sure this is something they can legally support.” Hungarian President László Sólyom last month declined Magyosz's request to refer the drug thrift law to the Constitutional Court for review. The drugmakers might refer the law to European Union competition authorities, Wessman said. Actavis, which expects as much as €23 million ($30.3 million) in revenue from Hungary this year, could see its Hungarian profit drop by as much as 50% because of the new regulations, he said.
According to Wessman's reading of the law, the state will assess the amount each drugmaker has to pay based upon the company's sales growth, not its absolute revenue. Generic-drug companies such as Actavis tend to have higher growth rates than those that sell expensive brand-name drugs, he said. „It discriminates between branded and generic companies,” Wessman said in a December 7 interview. Hungarian Health Ministry Press Officer Dóra Kádár said the government has not yet decided how it will assess each company's contribution toward paying down the state's drug deficit. (Bloomberg)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.